Kouji Joko

18PUBLICATIONS
28CO-AUTHORS
Infant and child healthCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 28, 2022
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.

Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada

|Jan 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.

Takeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada

|Jan 24, 2022
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.

Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki

|Nov 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada

|Sep 30, 2021
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.

Margherita Rimini, Shigeo Shimose, Sara Lonardi

|Jul 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.

Ilario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose

Pageof 3

Frequent Collaborators

11 joint publications

Toshifumi Tada

11 joint publications

Atsushi Hiraoka

11 joint publications

Yoichi Hiasa

8 joint publications

Kazuto Tajiri